Research Article| Volume 65, 103968, September 2022

Download started.


Evaluation of liver injury in multiple sclerosis patients receiving pulsed steroid therapy



      There is a paucity of literature about the methylprednisolone induced liver injury in multiple sclerosis (MS) patients. In this study, we intended to investigate the incidence, severity, and risk factors for liver injury in MS patients treated with pulsed methylprednisolone therapy.


      This is a prospective observational study on MS patients treated with methylprednisolone pulses. All MS subjects with relapses who were referred to Sina Hospital between May 2020 to May 2021 were included in the study. They were evaluated for the demographic, clinical characteristics, and liver function tests. Liver injury was diagnosed if there was an elevation of serum aminotransferase levels above the upper normal limit (45 IU/L).


      A total of 314 individuals participated in the study. The prevalence of liver injury after treatment with pulsed methylprednisolone therapy was 2.86%. None of the cases with liver injury were severe. Univariate regression analysis demonstrated that the patients with liver injury had a significantly higher frequency of hyperlipidemia (p: 0.002), alcohol abuse (p: 0.021), and non-alcoholic fatty liver disease (NAFLD) (p: 0.005) compared to those without liver injury. Multivariate regression analysis showed that hyperlipidemia (p: 0.04, odds ratio (OR): 6.31), and history of alcohol abuse (p: 0.007, OR: 36.71) were significantly associated with liver injury.


      Our study highlights the importance of a close follow-up of the liver function tests in MS patients following pulsed methylprednisolone therapy, particularly in patients with NAFLD, hyperlipidemia, and history of alcohol-abusing.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Acar M.
        • Gedizlioglu M.
        • Koskderelioglu A.
        • Ozturk F.
        • Kilinc S.
        • Talay N.
        Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse.
        Eur. Neurol. 2012; 68: 20-22
        • Berkovich R.
        Treatment of acute relapses in multiple sclerosis.
        Neurotherapeutics. 2013; 10: 97-105
        • Carrier P.
        • Godet B.
        • Crepin S.
        • Magy L.
        • Debette-Gratien M.
        • Pillegand B.
        • et al.
        Acute liver toxicity due to methylprednisolone: consider this diagnosis in the context of autoimmunity.
        Clin. Res. Hepatol. Gastroenterol. 2013; 37: 100-104
        • Chalasani N.P.
        • Hayashi P.H.
        • Bonkovsky H.L.
        • Navarro V.J.
        • Lee W.M.
        • Fontana R.J.
        ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.
        Am. J Gastroenterol. 2014; 109: 950-966
        • D’Agnolo H.M.A.
        • Drenth J.P.H.
        High-dose methylprednisolone-induced hepatitis in a patient with multiple sclerosis: a case report and brief review of literature.
        Neth. J. Med. 2013; 71: 199-202
        • Eguchi H.
        • Tani J.
        • Hirao S.
        • Tsuruta M.
        • Tokubuchi I.
        • Yamada K.
        • et al.
        Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves’ Orbitopathy.
        Int. J. Endocrinol. 2015; (2015)
        • Fardet L.
        • Kassar A.
        • Cabane J.
        • Flahault A.
        Corticosteroid-induced adverse events in adults: frequency, screening and prevention.
        Drug Saf. 2007; 30: 861-881
        • Gal R.L.
        • Vedula S.S.
        • Beck R.
        Corticosteroids for treating optic neuritis.
        Cochr. Datab. System. Rev. (Online). 2012; 4
        • Kimura H.
        • Takeda A.
        • Kikukawa T.
        • Hasegawa I.
        • Mino T.
        • Uchida-Kobayashi S.
        • et al.
        Liver injury after methylprednisolone pulse therapy in multiple sclerosis is usually due to idiosyncratic drug-induced toxicity rather than autoimmune hepatitis.
        Mult. Scler. Relat. Disord. 2020; 42102065
        • Kuraji R.
        • Sekino S.
        • Kapila Y.
        • Numabe Y.
        Periodontal disease–related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an emerging concept of oral-liver axis.
        Periodontology. 2021; 87 (2000): 204-240
        • Lal R.
        • Bell S.
        • Challenger R.
        • Hammock V.
        • Nyberg M.
        • Decker D.
        • et al.
        Pharmacodynamics and tolerability of repository corticotropin injection in healthy human subjects: a comparison with intravenous methylprednisolone.
        J. Clin. Pharmacol. 2016; 56: 195-202
        • Loraschi A.
        • Banfi P.
        • Mauri M.
        • Sessa F.
        • Bono G.
        • Cosentino M.
        Hepatotoxicity after high-dose methylprednisolone for demyelinating disease.
        Clin. Neuropharmacol. 2010; 33: 52-54
        • Lublin F.D.
        • Baier M.
        • Cutter G.
        Effect of relapses on development of residual deficit in multiple sclerosis.
        Neurology. 2003; 61: 1528-1532
        • Maàmouri N.
        • Ketari S.
        • Ben Hariz F.
        • Belkahla N.
        • Ben Romdhane S.
        • Chouaib S.
        • et al.
        Pulsed methylpresnisolone revealed autoimmune hepatitis in a patient with multiple sclerosis.
        J. Afr. d’Hepato-Gastroenterologie. 2009; 3: 195-197
        • Mansour-Ghanaei F.
        • Joukar F.
        • Mobaraki S.N.
        • Mavaddati S.
        • Hassanipour S.
        • Sepehrimanesh M.
        Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: a cross-sectional study in north of Iran.
        Diabet. Metab. Syndr. 2019; 13: 1591-1596
        • Naranjo C.A.
        • Busto U.
        • Sellers E.M.
        • Sandor P.
        • Ruiz I.
        • Roberts E.A.
        • et al.
        A method for estimating the probability of adverse drug reactions.
        Clin. Pharmacol. Ther. 1981; 30: 239-245
        • Nociti V.
        • Biolato M.
        • De Fino C.
        • Bianco A.
        • Losavio F.A.
        • Lucchini M.
        • et al.
        Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients.
        Brain Behav. 2018; 8: e00968
        • Polman C.H.
        • Reingold S.C.
        • Banwell B.
        • Clanet M.
        • Cohen J.A.
        • Filippi M.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria.
        Ann. Neurol. 2011; 69: 292-302
        • Thompson A.J.
        • Banwell B.L.
        • Barkhof F.
        • Carroll W.M.
        • Coetzee T.
        • Comi G.
        • et al.
        Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
        Lancet Neurol. 2018; 17: 162-173
        • Zoubek M.E.
        • Pinazo-Bandera J.
        • Ortega-Alonso A.
        • Hernández N.
        • Crespo J.
        • Contreras F.
        • et al.
        Liver injury after methylprednisolone pulses: a disputable cause of hepatotoxicity. A case series and literature review.
        Unit. Eur. Gastroenterol. J. 2019; 7: 825-837